Clinical trialNCT00454805CompletedPhase 2Interventional

AZD2171 in Addition to Fulvestrant in Patients With Advanced Breast Cancer.

SponsorAstraZenecaEnrollment75Advanced Breast Cancer

View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

The purpose of this study is to determine whether AZD2171 can effectively improve time to tumour progression when added to fulvestrant in patients with advanced hormone sensitive breast cancer who progressed on prior hormonal therapy.

clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a FindMyKOL profile link to it; the rest are shown as registered.

Bijoyesh Mookerjee, MD
AstraZeneca
Study Director
clinicaltrials.gov ↗

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

16 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

Australia

Research Site
Fitzroy, Australia
Research Site
Parkville, Australia
Research Site
Perth, Australia
Research Site
Waratah, Australia

Brazil

Research Site
Belo Horizonte, Brazil
Research Site
Curitiba, Brazil
Research Site
Fortaleza, Brazil
Research Site
Porto Alegre, Brazil
Research Site
Santro Andre, Brazil
Research Site
São Paulo, Brazil

United States

Research Site
Burbank, California, United States
Research Site
Los Angeles, California, United States
Research Site
Palm Springs, California, United States
Research Site
Boca Raton, Florida, United States
Research Site
Honolulu, Hawaii, United States
Research Site
New York, New York, United States

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Cediranib →Fulvestrant →

Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start: 31 Mar 2007
Primary completion: 31 Dec 2008
Completion: 30 Apr 2016
Last update posted: 3 Aug 2016
Registered enrollment: 75
Registry id: NCT00454805

clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; FindMyKOL does not interpret them.